ME stock icon

23andMe
ME

$0.42
1.51%
 

About: 23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.

Employees: 582

0
Funds holding %
of 6,702 funds
Analysts bullish %
0
News positive %
of 17 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

11% more call options, than puts

Call options by funds: $105K | Put options by funds: $95K

0% more funds holding in top 10

Funds holding in top 10: 6 [Q4 2023] → 6 (+0) [Q1 2024]

2% less repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 42

4.3% less ownership

Funds ownership: 43.19% [Q4 2023] → 38.89% (-4.3%) [Q1 2024]

13% less funds holding

Funds holding: 167 [Q4 2023] → 145 (-22) [Q1 2024]

47% less capital invested

Capital invested by funds: $123M [Q4 2023] → $65.2M (-$57.6M) [Q1 2024]

58% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 38

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$0.47
11%
upside
Avg. target
$0.47
11%
upside
High target
$0.47
11%
upside

1 analyst rating

positive
0%
neutral
100%
negative
0%
Citigroup
Daniel Grosslight
11%upside
$0.47
Neutral
Maintained
16 Apr 2024

Financial journalist opinion

Based on 17 articles about ME published over the past 30 days